巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Avita Medical

    RCEL
    5.570
    0.010
    0.18%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Avita Medical - 延遲價格・最後更新於 20/05 12:15
    最高位
    5.680
    最低位
    5.350
    開市價
    --
    前收市價
    5.560
    成交量(千)
    3.47
    成交額(百萬)
    0.18
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    139.00
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    22.490 - 5.060
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Avita Medical
    證券代碼
    RCEL.US
    所屬板塊
    Medical Devices
    公司業務
    Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
    發行量
    24925743
    公司總部
    28159 Avenue Stanford, Suite 220, Valencia
    公司網址
    https://www.avitamedical.com
    公司電話
    +1 661 367-9170
    暫無內容

    關於

    Avita Medical(RCEL.US)所屬的行業板塊為Medical Devices。
    Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
    詳細公司背景可參考: https://www.avitamedical.com